Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology最新文献

{"title":"Sociodemographic Disparities in Melanoma Stage at Diagnosis: The Role of Socioeconomic Status and Residential Location.","authors":"Danielle Gavanescu, Annette Dobson, Hansa Sharma, Samuel X Tan, Nicholas M Muller, Maria Celia B Hughes, Maryrose K Malt, B Mark Smithers, Kiarash Khosrotehrani, Lena A von Schuckmann","doi":"10.1158/1055-9965.EPI-25-0372","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0372","url":null,"abstract":"<p><strong>Background: </strong>Low tumour stage is associated with improved prognosis following diagnosis of primary melanoma. This study evaluated the associations between patient socioeconomic status (SES) and location of residence on tumour stage at melanoma diagnosis.</p><p><strong>Methods: </strong>Patients with a new diagnosis of histologically confirmed T1b-T4b melanoma in Queensland, Australia were recruited between 2010-2014. Logistic regression models were used to assess whether SES or location of residence were associated with lower (T1b-T3a) versus higher tumour stage (≥T3b).</p><p><strong>Results: </strong>Of 700 study participants with melanoma, those living in lower SES areas (n=358) had a higher likelihood of being diagnosed with ≥T3b-stage disease compared to patients in higher SES areas (n=342) (adjusted odds ratio [aOR] = 1.65, 95% confidence interval [CI]: 1.04-2.62, P =0.03). Relative to patients living in urban areas (n=389), patients living in inner regional areas (n=209) were more likely to be diagnosed with a ≥T3b-stage melanoma (OR = 1.65; 95% CI: 1.11-2.46; P = 0.01); however, this finding was not significant following adjustment for SES (aOR 1.17, 95% CI 0.72-1.91; P = 0.53).</p><p><strong>Conclusions: </strong>Patients residing in areas with lower average socioeconomic advantage were more frequently diagnosed with a locally advanced melanoma than patients in high SES areas. Geographical remoteness was not independently associated with tumour stage at diagnosis in this cohort.</p><p><strong>Impact: </strong>Our study highlights a disparity in early melanoma detection across socioeconomic classes. Population groups who are disproportionately more likely to be diagnosed with a thicker primary melanoma should be considered for targeted screening initiatives and healthcare accessibility programs.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of Comprehensive Inflammatory Lifestyle Score and association with colorectal cancer risk.","authors":"Jiali Zheng, Longgang Zhao, Jingwen Dong, Edward Giovannucci","doi":"10.1158/1055-9965.EPI-25-0386","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0386","url":null,"abstract":"<p><strong>Background: </strong>A comprehensive inflammatory lifestyle score (CILS) incorporating both dietary and non-dietary factors is lacking. This study aimed to develop and validate CILS and assess its association with colorectal cancer (CRC) risk.</p><p><strong>Methods: </strong>Eligible participants in the UK Biobank with data on baseline lifestyle factors and serum biomarkers measured 2 years later were randomly divided into training (N=4108) and validation (N=1760) datasets based on sex, age and race. Reduced rank regression followed by stepwise linear regression identified significant lifestyle factors (i.e., components of CILS) correlated with high-sensitivity C-reactive protein (hsCRP) and white blood count (WBC) from 24 a priori-selected inflammation-related factors. CILS was validated using multiple linear regression. Cox models were applied to examine the associations of CILS with incidence and mortality risk of CRC and subtypes in the remaining 182,814 participants.</p><p><strong>Results: </strong>CILS comprised three anti-inflammatory factors [low body weight (BMI<18.5), higher intake of fish, and apples/berries] and five pro-inflammatory factors [obesity/overweight, prolonged sedentary time (the highest tertile in the population), current smoking, whole-fat dairy, and processed meat] with higher CILS indicating a more proinflammatory lifestyle. Validation analyses demonstrated a 22.2% and 2.8% increase in hsCRP and WBC for each SD increment in CILS respectively. Higher CILS was linked to increased CRC incidence (HRper- SD-increase=1.12, 95%CI=1.08-1.16) and mortality (HRper- SD-increase=1.18, 95%CI=1.08-1.28), and increased risk of all CRC subtypes except incident rectal cancer.</p><p><strong>Conclusions: </strong>The validated hypothesis-driven and empirically-derived CILS was positively associated with CRC risk in the UK Biobank.</p><p><strong>Impact: </strong>CILS may offer promising applications in cancer prevention.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of cessation readiness among cigarette smokers presenting for low-dose computed tomography lung cancer screening in community settings (WF-20817CD).","authors":"Emily V Dressler, Kathryn E Weaver, Erin L Sutfin, Christina Bellinger, David P Miller, Derek Falk, W Jeffrey Petty, John Spangler, Rebecca Stone, Carol Kittel, Glenn J Lesser, Caroline Chiles, Jennifer A Lewis, Kristie Long Foley","doi":"10.1158/1055-9965.EPI-25-0293","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0293","url":null,"abstract":"<p><strong>Background: </strong>To plan cessation services and advance health equity, understanding factors related to cessation readiness and differences among patients presenting for lung cancer screening (LCS) is imperative.</p><p><strong>Methods: </strong>We recruited smoking patients aged 55-77 years presenting for LCS in 26 community-based imaging clinics participating in an NCI Community Oncology Research Program (NCORP) site-randomized trial (WF-20817CD, UG1CA189824). We collected outcomes of smoking cessation readiness to change and quitting self-efficacy immediately prior to screening. Linear mixed models were constructed with site random effects to assess associations of outcomes and baseline characteristics.</p><p><strong>Results: </strong>Participants (N=1,094; age=63.7; 81.9% White, 13.3% Black, 2.6% Hispanic, 2.3% American Indian; 20.2% non-metro) were even by gender (50.8% women) and educational attainment (51.1% ≤ high school education). Participants smoked an average of 17.2 cigarettes per day (SD=9.6), with mean pack year of 46.1 (SD=25.0). Predictors of increased cessation readiness included: being a man, increased worry about lung cancer, increased perceived benefits of quitting, quit attempt within past year, and smoking ≤ 10 cigarettes per day. For increased quitting self-efficacy: non-white race/ethnicity, men, less education, no use of other tobacco products, increased perceived benefits of quitting, quit attempt within past year, and smoking ≤ 10 cigarettes per day.</p><p><strong>Conclusions: </strong>To support cessation among patients undergoing LCS, imaging clinics and health systems should recognize pre-screening readiness to quit varies by population subgroups. Imaging clinics may benefit from a tailored approach that works with patients \"where they are.\"</p><p><strong>Impact: </strong>These findings suggest that gender, race and ethnicity are associated with smoking cessation readiness and quitting self-efficacy.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective examination of cellular and soluble mediators of immune dysregulation and their association with lung cancer risk.","authors":"Umayal Sivagnanalingam, Kathryn Demanelis, Renwei Wang, Jian-Min Yuan, Olivera J Finn","doi":"10.1158/1055-9965.EPI-25-0279","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0279","url":null,"abstract":"<p><strong>Background: </strong>There are currently no blood-based biomarkers for early detection of lung cancer. We explored cellular and soluble mediators of immune dysregulation as potential biomarkers of lung cancer risk and development. We conducted a prospective nested case-control study of incident lung cancer cases and individually matched healthy controls from the Pittsburgh Lung Screening Study (PLuSS) cohort of current and former smokers at high risk for developing lung cancer.</p><p><strong>Methods: </strong>Peripheral blood mononuclear cells (PBMCs) were analyzed by Flow Cytometry, and Meso Scale Discovery multiplex platform immunoassay was used for detection of serum cytokines and chemokines at a distal (~7 years prior) and a proximal (~9 months prior) timepoint prior to cancer diagnosis. A linear mixed model was used to assess differences of analytes between cases and controls. Conditional logistic regression models were used to evaluate associations between levels of analytes and lung cancer risk.</p><p><strong>Results: </strong>No significant PBMC differences were found between cases and controls. Serum interleukin-6 (IL-6), IL-12/IL-23p40, IL-17A, and tumor-necrosis factor-α (TNFα) were significantly higher in cases than controls (P < 0.05) at the proximal timepoint. Cases had higher levels of angiogenic protein-placental growth factor (PlGF) in sera from both distal and proximal timepoints (P < 0.05). Doubling concentrations of these analytes were associated with a 40% to 300% increase in lung cancer risk (P < 0.05).</p><p><strong>Conclusions: </strong>These circulating candidate biomarkers warrant further validation for early detection of lung cancer and identification of elevated risk.</p><p><strong>Impact: </strong>If validated in larger studies, these biomarkers could have clinical relevance.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Changes in Obesity and Abdominal Obesity on Endometrial Cancer Risk in Young Korean Women: A Nationwide Cohort Study.","authors":"Jung Heo, Hyunjyung Oh, Yong Sang Song, Yeon Jee Lee, Kyungdo Han, Min-Kyung Lee","doi":"10.1158/1055-9965.EPI-25-0615","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0615","url":null,"abstract":"<p><strong>Background: </strong>The rising incidence of endometrial cancer in young women parallels the increasing prevalence of obesity, a well-established risk factor. However, the impact of longitudinal changes in obesity and abdominal obesity on early-onset endometrial cancer remains insufficiently understood.</p><p><strong>Methods: </strong>This nationwide cohort study utilized data from the Korean National Health Insurance Service. Women aged 20-39 years who underwent two health examinations at a three-year interval between 2009 and 2015, with no history of cancer, were included. Participants were categorized based on changes in obesity (BMI ≥25 kg/m²) or abdominal obesity (waist circumference ≥85 cm) into four groups: stable non-obese, non-obese to obese, obese to non-obese, and stable obese. The risk of endometrial cancer was assessed using Cox proportional hazards models.</p><p><strong>Results: </strong>Among 935,600 women, 798 developed endometrial cancer. Compared to the stable non-obese group, adjusted hazard ratios (HRs) for endometrial cancer were 1.940 (1.468-2.563), 2.083 (1.447-3.001), and 2.083 (1.447-3.001) in the non-obese to obese, obese to non-obese, and stable obese groups, respectively. Regarding abdominal obesity, the adjusted HRs were 2.048 (1.581-2.651), 2.302 (1.684-3.146), and 4.394 (3.557-5.427), respectively. The risk of cancer was higher in the obese to non-obese group than in the non-obese to obese group.</p><p><strong>Conclusion: </strong>Changes in obesity and abdominal obesity status were associated with early-onset endometrial cancer, with persistent abdominal obesity showing the highest risk.</p><p><strong>Impact: </strong>These findings support the need for early, sustained obesity interventions to reduce endometrial cancer risk in young women.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LATE-STAGE OUTCOMES AS SURROGATES FOR MORTALITY IN CANCER SCREENING TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS.","authors":"Matejka Rebolj, Adam R Brentnall, Julia Geppert, Nefeli Kouppa, Bethany Shinkins, Karoline Freeman, Chris Stinton, Matthew J Randell, Samantha Johnson, Robert A Smith, Peter Sasieni, Sam M Janes, Ruth Etzioni, Stephen W Duffy, Sian Taylor-Phillips","doi":"10.1158/1055-9965.EPI-25-0201","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0201","url":null,"abstract":"<p><p>Late-stage cancer incidence has been proposed as a surrogate outcome for cancer-specific mortality in future screening trials. Two previous meta-analyses with 33 and 39 trials assessed trial-level surrogacy but provided inconsistent conclusions about the suitability of late-stage cancer endpoints replacing mortality. Our systematic review and meta-analysis (PROSPERO, CRD42023369320) investigated the association between the effect of cancer screening on incidence of late-stage cancer and cancer-specific mortality. From 57 trials with 61 trial arm comparisons, correlation between late-stage incidence and mortality outcomes was 0.69 (95% confidence interval (CI): 0.47-0.84) for all cancers combined. Specifically, correlations were: 0.58 (0.27-0.93) for bowel (N=11 trials), 0.79 (0.49-0.94) for breast (N=13), and 0.91 (0.84-0.96) for lung cancer (N=14). Trial point estimates of the screening effect on mortality were within each trial's 95% CI late-stage incidence estimates in 56/61 (92%) trial-arm comparisons, and in 16/19 (84%) trial arm comparisons where the entire 95% CI for screening effect on late-stage incidence was below 1. Evidence suggests potential for late-stage cancer incidence as a key outcome in screening trials, but further research is needed to clarify when to measure late-stage outcomes, extrapolation for cancer types without trials, and the conditions when late-stage cancer does not accurately predict mortality.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnic Demographic Shifts and the Rise of Early-Onset Esophageal, Gastric and Colorectal Malignancies in the United States.","authors":"Elaine Chiao, Tevan Luong, Aditya Mahadevan, Farshid Dayyani","doi":"10.1158/1055-9965.EPI-25-0040","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0040","url":null,"abstract":"<p><p>The incidence of early-onset gastric, esophageal, and colorectal cancers has risen rapidly in the U.S. over the past two decades. Genetic predisposition, environmental exposures, and lifestyle factors contribute to these trends, particularly among Hispanic and East Asian patients. This study examines epidemiological influences underlying this growing burden. Recent research highlights genetic susceptibilities, environmental exposures, and dietary habits, such as higher H. pylori prevalence and cancer-associated polymorphisms, as key risk factors. Hispanic patients experience younger-onset gastric cancer and higher rates of non-cardia gastric and advanced-stage colorectal cancer. Additionally, studies highlight East Asia as a region with some of the highest rates of gastrointestinal cancer incidence and mortality. While the specific incidence among early-onset cases remains relatively understudied, preliminary evidence suggests a rising trend in early-onset gastrointestinal cancers in this region. Despite advancements in targeted therapies, young patients face higher cancer-specific mortality. The rising Hispanic and East Asian populations in the U.S. may contribute to increasing early-onset gastrointestinal malignancies due to their unique genetic and environmental susceptibilities. This study is the first to explore the connection between demographic shifts and rising cancer incidence in young Hispanic and East Asian populations. Further research is needed to better characterize and mitigate these concerning trends.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ambient Fine Particulate Matter, Residential Greenness, and Childhood Cancer Risk by Trimester of Exposure in Minnesota 2000-2014: A Case-control Study.","authors":"Cassandra J Clark, David Haynes, Zhanni Lu, Jeannette M Sample, Laura A McGuinn, Thanh T Hoang, Philip J Lupo, Michael E Scheurer, Erin L Marcotte, Lindsay A Williams","doi":"10.1158/1055-9965.EPI-25-0465","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0465","url":null,"abstract":"<p><strong>Background: </strong>Outdoor air pollution is a suspected risk factor for childhood cancer, and there is some evidence that greenness may reduce cancer risk. We examined relationships between prenatal exposure to ambient fine particle air pollution (PM2.5), greenness, and childhood cancer risk in Minnesota.</p><p><strong>Methods: </strong>Cases included individuals born in the state of Minnesota and reported to the Minnesota Cancer Reporting System between 2000-2014 (n=1272, aged 0-14yrs at diagnosis) and birthyear-matched cancer-free controls (n=5245). We used Network Common Data Form to estimate monthly PM2.5 exposure and the Normalized Difference Vegetation Index (NDVI) for census tract-level greenness. We estimated odds ratios (OR) and 95% confidence intervals (95%CI) between high PM2.5 (≥12 µg/m³) and NDVI (≥ 0.3) exposure and each childhood cancer per trimester (T1, T2, T3) and full pregnancy (FP) using adjusted logistic regression.</p><p><strong>Results: </strong>High PM2.5 exposure was associated with increased odds of Burkitt lymphoma (ORT1: 1.93 [1.13-3.30]), lymphoreticular neoplasms (ORT1: 1.43 [1.01-2.01]), Hodgkin lymphoma (ORT2: 2.60 [1.52-4.45]), lymphoid leukemias (ORT3: 1.17 [1.01-1.37]), B-cell leukemia (ORT3: 1.20 [1.02-1.41]), and intracranial and intraspinal embryonal neoplasms (ORT3: 1.90 [1.07-3.37]). High residential greenness during early life was associated with reduced risk of malignant epithelial neoplasms and melanomas (ORT1: 0.34 [0.13-0.91]). Unexpectedly, greenness was also associated with increased risk of renal tumors (ORT2: 1.52 [1.11-2.08]; ORFP: 1.30 [0.98-1.72)) and neuroblastoma (ORT3: 1.44 [1.03-2.03]).</p><p><strong>Conclusions: </strong>We observed elevated risk associated with PM2.5 exposure throughout pregnancy for multiple individual cancers, namely leukemias, lymphomas, and CNS tumors.</p><p><strong>Impact: </strong>These findings demonstrate the complex relationship between PM2.5 and greenness.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term trends in bladder cancer incidence using a harmonized staging variable - A SEER-based study.","authors":"Praveen Kumar, Jennifer Ruhl, Tanvi V Chiddarwar, David U Garibay-Treviño, Krishna Roy Chowdhury, Prince P Osei, Fernando Alarid-Escudero, Bruce L Jacobs, Karen M Kuntz, Hawre Jalal","doi":"10.1158/1055-9965.EPI-25-0210","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0210","url":null,"abstract":"<p><strong>Background: </strong>Coding changes in disease definitions have influenced trends in bladder cancer epidemiologic outcomes in registries. The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable (available by request to the SEER Program) for long-term trend analysis. This study analyzes trends in bladder cancer incidence using the harmonized staging variable.</p><p><strong>Methods: </strong>Using SEER 12 registry data, we compared trends in the incidence of bladder cancer cases diagnosed during 1992-2019 using the revised (or harmonized) staging variable against the original staging variables (SEER modified AJCC 3rd edition for 1992-2003, Derived AJCC 6th edition for 2004-15, Derived SEER Combined for 2016-17, Derived EOD 2018 for 2018-2019). We used JoinPoint regression to analyze changes in trends.</p><p><strong>Results: </strong>The data availability has improved with the revised staging system as the proportion of cases with missing N (lymph node), and M (metastasis) stages was substantially reduced. However, the trends varied by T stages between the two systems. There were generally more discontinuities in trends with the original system than with the revised system. Unlike the trend observed with the original staging system, the harmonized staging system has shown a 4% annual decrease in Tis incidence since 1992.</p><p><strong>Conclusions: </strong>With the revised variable, we observed a consistent decrease in the incidence of Tis cases, and the trends appear smoother.</p><p><strong>Impact: </strong>Our study highlights the benefits of using revised staging variables to reveal previously hidden patterns, supporting the use of new variables for a more nuanced understanding of temporal trends in epidemiology.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of HPV self-collection compared to clinician-collected HPV testing and cytology: a meta-analysis.","authors":"Sarah A Phillips, Sophie Denoël, Nicolas Wentzensen, Marc Arbyn","doi":"10.1158/1055-9965.EPI-25-0362","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-25-0362","url":null,"abstract":"<p><p>Meta-analyses show comparable clinical accuracy of PCR-based HPV assays on self- compared to clinician-collected specimens. We extended these meta-analyses by comparing HPV testing on both samples with cytology from clinician-collected specimens. Studies published in PubMed, Embase, and Cochrane Library up to September 2024 were reviewed for inclusion. Studies had to report paired HPV self-collection, clinician-collected HPV testing and cytology. Performance measures included sensitivity and specificity of atypical squamous cells of undetermined significance (ASC-US) or worse and hrHPV positivity in self- and clinician-collected samples for cervical intraepithelial neoplasia 2 or worse (CIN2+). Accuracy data was pooled using the bivariate normal model for logit transforms of sensitivity and specificity. Sixteen full-text articles met inclusion criteria. Studies were heterogeneous and included referral populations, which may overestimate cytology sensitivity. Cytology was less sensitive in detecting CIN2+ (pooled sensitivity 87%, 95% CI 76-93) compared to HPV testing on self- (90%) and clinician-collected samples (93%) when restricting to PCR-based HPV assays. Overall, HPV self-collection sensitivity surpassed clinician-collected cytology testing, demonstrating that 3-year screening intervals, which are recommended for negative cytology results, are safe to use for negative HPV results from self-collected specimens. Longitudinal data of HPV testing on self- compared to clinician-collected samples are lacking.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}